These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 28391657)

  • 1. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
    Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
    Papp K; Reich K; Leonardi CL; Kircik L; Chimenti S; Langley RG; Hu C; Stevens RM; Day RM; Gordon KB; Korman NJ; Griffiths CE
    J Am Acad Dermatol; 2015 Jul; 73(1):37-49. PubMed ID: 26089047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
    Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.
    Fiorillo L; Becker E; de Lucas R; Belloni-Fortina A; Armesto S; Elewski B; Maes P; Oberoi RK; Paris M; Zhang W; Zhang Z; Arkin L
    J Am Acad Dermatol; 2024 Jun; 90(6):1232-1239. PubMed ID: 38266683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
    J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R; Alikhan A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J; Thaçi D; Joly P; Peris K; Papp KA; Goncalves J; Day RM; Chen R; Shah K; Ferrándiz C; Cather JC
    J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
    Bissonnette R; Haydey R; Rosoph LA; Lynde CW; Bukhalo M; Fowler JF; Delorme I; Gagné-Henley A; Gooderham M; Poulin Y; Barber K; Jenkin P; Landells I; Pariser DM
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):403-410. PubMed ID: 29055155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.